OR WAIT null SECS
September 03, 2024
Bio/pharma companies should be approaching their decarbonization journey as a strategic business move for the future as industry stakeholders are placing greater value on sustainability.
August 30, 2024
The approach makes use of clinical mass spectrometers that are already available in hospitals around the world.
August 29, 2024
This is the company’s largest single investment in the Sweden Biomanufacturing Center, in Södertälje, which opened in 2021.
Phase III trial results showed that Imfinzi (durvalumab in combination with chemotherapy reduced the risk of recurrence, progression, or death by 32% in patients with resectable non-small cell lung cancer before and after surgery.
August 28, 2024
The completed acquisition of Morphic expands Lilly's immunology pipeline with Morphic's oral integrin therapies for treating inflammatory bowel disease.
August 27, 2024
PiaSky (crovalimab) has previously been approved in countries such as the United States and Japan for monthly, subcutaneous use that may be self-administered with adequate training.
August 26, 2024
Opaganib was given orphan drug designation for the treatment of neuroblastoma in children, which is rare, but the most common infancy malignancy.
In a 24-week study of patients with PAH, six-minute walking distance improved by an average of 40.8 meters, and risk of death or clinical worsening was reduced by 82%.
August 23, 2024
The collaboration builds on Novartis’ acquisition of Chinook Therapeutics just over a year ago.
August 22, 2024
The approvals and authorizations come amid a late summer surge in the virus that is tracking a bit earlier than the early fall wave in the US in 2023.
